MAPK3 and non-small cell lung carcinoma: As pembrolizumab interacts with PD-1, we hypothesised that blocking the intracellular signalling could also affect the cell proliferation of NSCLC cells, as described by mean of the inhibition of the canonical signalling pathways, i.e. the AKT and ERK1/2 pathways (43).